
STAMINA reported favorable vascular-marker changes in a small supplement trial. A closer look at the results, incomplete follow-up and evidence limits.

On November 4, 2026, MedicalXpress reported on the University of Surrey's published STAMINA trial, which tested a multicomponent supplement over six months.
The STAMINA researchers reported favorable differences between the supplement and control groups in three vascular measurements: flow-mediated dilation, arterial stiffness and systolic blood pressure. The primary result concerned how an artery responds to increased blood flow. For longevity research, this is a preliminary signal about vascular function rather than evidence of reduced biological age or longer life. Its value lies in identifying a result that further research can test against meaningful health outcomes.
Study type: A randomized trial in humans, not an in vitro experiment or an animal study.
According to the study details accompanying the MedicalXpress report, STAMINA was a randomized, double-blind controlled trial. Researchers assigned participants to a multicomponent supplement or a control and assessed vascular measurements over six months. The study randomized 61 people.
The relevant results were adjusted differences between the groups. They were not simply descriptions of how much the supplement group's measurements changed from their own starting values. That distinction matters when a headline compresses a controlled trial into a claim that a product “improved vascular health.”
An adjusted between-group difference describes the contrast estimated in the study's analysis. It should not be presented as the change that every participant experienced. Keeping the comparison and measurement units visible helps preserve what the experiment actually found.
The primary outcome was brachial artery flow-mediated dilation, abbreviated as FMD. This measures endothelial function through an artery's widening in response to increased blood flow. In plain language, the study examined a specific aspect of blood-vessel responsiveness.
The researchers reported an adjusted between-group FMD difference of +2.9 percentage points at six months. The direction favored the supplement group. The unit matters: the finding was expressed in percentage points on the FMD measure.
Endothelial function is also studied outside supplement research. A systematic review of randomized aerobic-exercise trials examined this endpoint alongside other cardiovascular markers. That provides context for the kind of measurement used in STAMINA, not a comparison of the effects of exercise and this formulation.
The useful question is therefore specific: did this formulation affect the selected vascular endpoint under the study's conditions? That question is narrower than whether it changed aging as a whole. AgeAmaze's guide to interpreting trial endpoints and evidence provides a framework for keeping those questions separate.
The STAMINA researchers also reported an adjusted between-group difference of −1.18 m/s in PWV, the study's arterial-stiffness measurement. The corresponding difference in systolic blood pressure was −6.1 mmHg. Both results favored the supplement group at six months.
These findings broadened the vascular picture beyond the primary FMD outcome. They concerned different measurements, so they should remain separately identified rather than being combined into a single claim about rejuvenation. The clearest account preserves the endpoint attached to each result.
Blood lipids did not differ significantly between groups, according to the researchers. This is an important part of the overall result rather than a detail to leave out of an otherwise favorable summary. The trial's reported pattern was selective: several vascular measures favored the supplement while lipid levels did not show a significant between-group difference.
The estimated 10-year cardiovascular-risk score also shifted modestly in favor of the supplement group. The researchers said that difference was driven primarily by systolic blood pressure. Its interpretation therefore depends heavily on the blood-pressure finding already described.
The score should be read as an estimate rather than a separate observed health outcome. Presenting the blood-pressure difference and the risk-score difference as wholly independent evidence would overstate how much distinct information they provide. A careful summary explains their connection.
For readers interested in biological-age testing, this illustrates why the identity of a measurement matters as much as its direction. A favorable result needs to retain its original meaning as it moves from a paper into a headline. The broader challenge is connecting biomarker signals with meaningful health outcomes, rather than treating every favorable measurement as interchangeable evidence.
MedicalXpress quoted Surrey cardiovascular-medicine professor Christian Heiss describing favorable vascular-biomarker changes. Surrey founding dean Juliet Wright called the findings a “proof of concept.” Those descriptions fit a study whose limitations remain central to its interpretation:
For readers evaluating a supplement claim, the practical task is to match the wording to the measured outcome. Look for the actual endpoint and the population studied before considering the broader interpretation. A claim about FMD should remain a claim about FMD unless additional evidence supports a wider conclusion.
The same discipline applies when comparing future studies. Ask whether they repeat the original endpoint or test a more direct health outcome. These are different contributions to the evidence base, and both should be described accurately. Personal decisions about supplements or cardiovascular care belong in a discussion with a qualified healthcare professional rather than being inferred from this experiment alone.
The next logical step is independent replication in larger and more diverse populations, followed by longer-term research testing whether the vascular changes translate into meaningful clinical benefits.
Following STAMINA means assessing how later supplement claims relate to the measurements behind them, a task AgeAmaze supports with clear explanations of longevity research. When vascular findings are recast as biological-age benefits, AgeAmaze helps research-minded adults distinguish established evidence from preliminary interpretations without turning emerging interventions into promises.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog